Alterations of somatostatin and its modulation by levodopa in MPTP-treated mouse brain

Masato Asanuma, Norio Ogawa, Yukiko H. Sora, Khitisak Pongdhana, Kumiko Haba, Akitane Mori

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We examined the changes in the concentrations of neuropeptides in various regions of the mouse brain 1, 2 or 6 weeks after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment (30 mg/kg i.p. twice/day for 5 days) and further examined the effects of levodopa injections (200 mg/kg i.p.) for 14 days starting 4 weeks after MPTP treatment on regional somatostatin (SRIF) concentrations. Substance P, cholecystokinin-octapeptide and thyrotropin-releasing hormone did not show any significant changes up to 6 weeks after MPTP treatment, whereas the SRIF concentration increased 1 week after MPTP treatment but decreased thereafter, showing a marked decrease in the striatum and hippocampus after 6 weeks. In the striatum, the decreased concentration of SRIF recovered to the normal level with levodopa injections. This SRIF depletion could be a change secondary to dopamine depletion. On the other hand, in the cerebral cortex, while showing no change in the SRIF concentration after MPTP treatment, the concentration decreased significantly with levodopa injections. In the hippocampus, the decreased SRIF levels were still low after levodopa treatment. Since it has been reported that SRIF concentrations are significantly reduced in the frontal cortex and hippocampus of demented parkinsonians and patients with senile dementia of the Alzheimer type and that levodopa treatment induced various psychiatric side effects, the results of the present study suggest some relationship among levodopa treatment, SRIF depletion and the demented state.

Original languageEnglish
Pages (from-to)155-160
Number of pages6
JournalJournal of the Neurological Sciences
Volume100
Issue number1-2
DOIs
Publication statusPublished - 1990

Fingerprint

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Levodopa
Somatostatin
Brain
Hippocampus
Therapeutics
Injections
Sincalide
Thyrotropin-Releasing Hormone
Frontal Lobe
Neuropeptides
Cerebral Cortex
Psychiatry
Dopamine
Alzheimer Disease

Keywords

  • Dementia
  • Levodopa
  • MPTP
  • Parkinson's disease
  • Somatostatin

ASJC Scopus subject areas

  • Ageing
  • Clinical Neurology
  • Surgery
  • Neuroscience(all)
  • Developmental Neuroscience
  • Neurology

Cite this

Alterations of somatostatin and its modulation by levodopa in MPTP-treated mouse brain. / Asanuma, Masato; Ogawa, Norio; Sora, Yukiko H.; Pongdhana, Khitisak; Haba, Kumiko; Mori, Akitane.

In: Journal of the Neurological Sciences, Vol. 100, No. 1-2, 1990, p. 155-160.

Research output: Contribution to journalArticle

Asanuma, Masato ; Ogawa, Norio ; Sora, Yukiko H. ; Pongdhana, Khitisak ; Haba, Kumiko ; Mori, Akitane. / Alterations of somatostatin and its modulation by levodopa in MPTP-treated mouse brain. In: Journal of the Neurological Sciences. 1990 ; Vol. 100, No. 1-2. pp. 155-160.
@article{b6bc4c32c8534f65a11d9e713991cfa0,
title = "Alterations of somatostatin and its modulation by levodopa in MPTP-treated mouse brain",
abstract = "We examined the changes in the concentrations of neuropeptides in various regions of the mouse brain 1, 2 or 6 weeks after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment (30 mg/kg i.p. twice/day for 5 days) and further examined the effects of levodopa injections (200 mg/kg i.p.) for 14 days starting 4 weeks after MPTP treatment on regional somatostatin (SRIF) concentrations. Substance P, cholecystokinin-octapeptide and thyrotropin-releasing hormone did not show any significant changes up to 6 weeks after MPTP treatment, whereas the SRIF concentration increased 1 week after MPTP treatment but decreased thereafter, showing a marked decrease in the striatum and hippocampus after 6 weeks. In the striatum, the decreased concentration of SRIF recovered to the normal level with levodopa injections. This SRIF depletion could be a change secondary to dopamine depletion. On the other hand, in the cerebral cortex, while showing no change in the SRIF concentration after MPTP treatment, the concentration decreased significantly with levodopa injections. In the hippocampus, the decreased SRIF levels were still low after levodopa treatment. Since it has been reported that SRIF concentrations are significantly reduced in the frontal cortex and hippocampus of demented parkinsonians and patients with senile dementia of the Alzheimer type and that levodopa treatment induced various psychiatric side effects, the results of the present study suggest some relationship among levodopa treatment, SRIF depletion and the demented state.",
keywords = "Dementia, Levodopa, MPTP, Parkinson's disease, Somatostatin",
author = "Masato Asanuma and Norio Ogawa and Sora, {Yukiko H.} and Khitisak Pongdhana and Kumiko Haba and Akitane Mori",
year = "1990",
doi = "10.1016/0022-510X(90)90027-K",
language = "English",
volume = "100",
pages = "155--160",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Alterations of somatostatin and its modulation by levodopa in MPTP-treated mouse brain

AU - Asanuma, Masato

AU - Ogawa, Norio

AU - Sora, Yukiko H.

AU - Pongdhana, Khitisak

AU - Haba, Kumiko

AU - Mori, Akitane

PY - 1990

Y1 - 1990

N2 - We examined the changes in the concentrations of neuropeptides in various regions of the mouse brain 1, 2 or 6 weeks after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment (30 mg/kg i.p. twice/day for 5 days) and further examined the effects of levodopa injections (200 mg/kg i.p.) for 14 days starting 4 weeks after MPTP treatment on regional somatostatin (SRIF) concentrations. Substance P, cholecystokinin-octapeptide and thyrotropin-releasing hormone did not show any significant changes up to 6 weeks after MPTP treatment, whereas the SRIF concentration increased 1 week after MPTP treatment but decreased thereafter, showing a marked decrease in the striatum and hippocampus after 6 weeks. In the striatum, the decreased concentration of SRIF recovered to the normal level with levodopa injections. This SRIF depletion could be a change secondary to dopamine depletion. On the other hand, in the cerebral cortex, while showing no change in the SRIF concentration after MPTP treatment, the concentration decreased significantly with levodopa injections. In the hippocampus, the decreased SRIF levels were still low after levodopa treatment. Since it has been reported that SRIF concentrations are significantly reduced in the frontal cortex and hippocampus of demented parkinsonians and patients with senile dementia of the Alzheimer type and that levodopa treatment induced various psychiatric side effects, the results of the present study suggest some relationship among levodopa treatment, SRIF depletion and the demented state.

AB - We examined the changes in the concentrations of neuropeptides in various regions of the mouse brain 1, 2 or 6 weeks after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment (30 mg/kg i.p. twice/day for 5 days) and further examined the effects of levodopa injections (200 mg/kg i.p.) for 14 days starting 4 weeks after MPTP treatment on regional somatostatin (SRIF) concentrations. Substance P, cholecystokinin-octapeptide and thyrotropin-releasing hormone did not show any significant changes up to 6 weeks after MPTP treatment, whereas the SRIF concentration increased 1 week after MPTP treatment but decreased thereafter, showing a marked decrease in the striatum and hippocampus after 6 weeks. In the striatum, the decreased concentration of SRIF recovered to the normal level with levodopa injections. This SRIF depletion could be a change secondary to dopamine depletion. On the other hand, in the cerebral cortex, while showing no change in the SRIF concentration after MPTP treatment, the concentration decreased significantly with levodopa injections. In the hippocampus, the decreased SRIF levels were still low after levodopa treatment. Since it has been reported that SRIF concentrations are significantly reduced in the frontal cortex and hippocampus of demented parkinsonians and patients with senile dementia of the Alzheimer type and that levodopa treatment induced various psychiatric side effects, the results of the present study suggest some relationship among levodopa treatment, SRIF depletion and the demented state.

KW - Dementia

KW - Levodopa

KW - MPTP

KW - Parkinson's disease

KW - Somatostatin

UR - http://www.scopus.com/inward/record.url?scp=0025694842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025694842&partnerID=8YFLogxK

U2 - 10.1016/0022-510X(90)90027-K

DO - 10.1016/0022-510X(90)90027-K

M3 - Article

C2 - 1708406

AN - SCOPUS:0025694842

VL - 100

SP - 155

EP - 160

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -